APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria

Autor:	Pascal Deschatelets, Humphrey Pullon, Carolina Vega, Federico Grossi, Delphine El Mehdi, Lisa Tan, Cedric G. Francois
Rok vydání:	2017
Předmět:	0301 basic medicine business.industry Immunology medicine.disease Complement (complexity) 03 medical and health sciences 030104 developmental biology Extravascular hemolysis Paroxysmal nocturnal hemoglobinuria medicine In patient business Molecular Biology
Zdroj:	Molecular Immunology. 89:115
ISSN:	0161-5890
DOI:	10.1016/j.molimm.2017.06.039
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::15dc8abcdb80d5577d0a5e3f78a98d20 https://doi.org/10.1016/j.molimm.2017.06.039 Zobrazit plný text záznamu Full Text from ScienceDirect